GlassScriptPhysician profile
Leandra Rene Debono
NPI 1609557073
$3,502.80
in general payments reported to CMS, 2019-2025
8 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $747 · 2024: $2,161 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,134 · Travel and Lodging: $1,361 · Education: $7.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,134.46 |
| Travel and Lodging | $1,360.91 |
| Education | $7.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,496.75 | 2024-2025 | Acuvue |
| Alcon Vision LLC | $1,029.79 | 2023-2025 | Precision7, Total30, Precision 1 |
| Biotissue Holdings INC. | $331.64 | 2024 | |
| Amgen INC. | $279.67 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $176.25 | 2024-2025 | Xiidra, Miebo |
| Lkc Technologies, INC. | $132.24 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $30.66 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $25.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leandra Debono listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.